Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The second generation type II JAK2 inhibitor, AJ1-10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I JAK2 inhibitors in models of myeloproliferative neoplasms (MPNs)
    Meeting Abstract

    Rai, S.; Stetka, J.; Usart, M.; Hao-Shen, H.; Park, Y.; Houston, R.; Martinez Benitez, A. R.; Wereski, M.; Guzzardi, E.; Persaud, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 1a/b dose escalation study of the FLT3/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Goldberg, A. D.; Ohanian, M.; Koller, P. B.; Cherry, M.; Altman, J. K.; Tomlinson, B.; Chandhok, N. S.; Haney, D. N.; Hu, J.; Sinha, R. K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Intensive therapy for NPM1 mutant AML patients: Negative impact of FLT3-ITD(high)but not FLT3-ITD(low) and FLT3TKD and role of transplant in patients over 60 years of age
    Meeting Abstract

    Winer, E. S.; Flamand, Y.; Shallis, R. M.; Stempel, J. M.; Goldberg, A. D.; Stahl, M. F.; Patel, A. A.; Duvall, A. S.; Abaza, Y.; Oh, T. S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Entospletinib (ENTO) in combination with cytarabine (Ara-C) and daunorubicin (DNR) in newly diagnosed (ND) adult patients with NPM1-mutated and FLT3-ITD wild-type acute myeloid leukemia (AML) Is associated with good response and survival: A phase 2 sub-study of the beat AML master trial
    Meeting Abstract

    Borate, U.; Li, R.; Huang, Y.; Swords, R. T.; Traer, E.; Stein, E.; Foran, J. M.; Baer, M. R.; Duong, V. H.; Stock, W.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with TP53-mutated AML after first relapse or with primary refractory disease: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND)
    Meeting Abstract

    Badar, T.; Atallah, E. L.; Saliba, A. N.; Shallis, R. M.; Stahl, M. F.; Bewersdorf, J. P.; Correia, G. S. D.; Patel, A. A.; Abaza, Y.; Murthy, G. S. G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tracking immune reconstitution in the bone marrow following allogeneic hematopoietic transplantation in humans reveals early dominance of innate lymphoid populations
    Meeting Abstract

    DeWolf, S.; Kuttiyara, J.; Vinci, P.; Slingerland, J.; Marcello, L. T.; Giardina, P. A.; Donohoe, W.; Lin, R. J.; Papadopoulos, E. B.; Gyurkocza, B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Interim phase I clinical data of FT819-101, a study of the first-ever, off-the-shelf, iPSC-derived TCR-less CD19 CAR T-cell therapy for patients with relapsed/refractory B-cell malignancies
    Meeting Abstract

    Mehta, A.; Farooq, U.; Chen, A.; McGuirk, J. P.; Ly, T.; Wong, L.; Cooley, S.; Valamehr, B.; Elstrom, R.; Chu, Y. W.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Initiating first-line (1L) Ibrutinib (Ibr) in patients (pts) with chronic lymphocytic leukemia (CLL) improves overall survival (OS) outcomes to rates approximating an age-matched population of ≥65 years
    Meeting Abstract

    Ghia, P.; Owen, C.; Barrientos, J. C.; Barr, P. M.; Mato, A. R.; Shi, C. X.; Szoke, A.; Abbazio, C.; Krigsfeld, G. S.; Burger, J. A.
    Blood (2022)

    Fulltext@MSK | Save
  • Comparing acalabrutinib and ibrutinib in the real world: A study of 2,509 patients with chronic lymphocytic leukemia
    Meeting Abstract

    Roeker, L. E.; DerSarkissian, M.; Ryan, K. J.; Chen, Y.; Wahlstrom, S. K.; Hakre, S.; Yu, L.; Guo, H.; Mato, A. R.
    Blood (2022)

    Fulltext@MSK | Save
  • Mutational profile of children with myeloproliferative neoplasms
    Meeting Abstract

    Rutherford, K.; Farnoud, N.; Krishnan, A.; Rampal, R. K.; Levine, R. L.; Kucine, N.
    Blood (2022)

    Fulltext@MSK | Save